Scholarlink

<p>Breast cancer remains the leading cause of cancer-related mortality among women worldwide. Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a critical therapeutic option, particularly for patients with triple-negative breast cancer and other HER2-negative metastatic breast cancer harboring <i>BRCA</i> mutations. Despite their clinical success, the emergence of primary and acquired resistance to PARP inhibitors poses a significant challenge, limiting their long-term effectiveness. Here we provide a comprehensive overview of the mechanisms underlying the action of PARP inhibitors, as well as their clinical development and application. In addition, we discuss the factors driving resistance and potential strategies to overcome it in the context of PARP inhibitors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Weiyun Wang,
  • Chenghui Cai,
  • Sisi Qin,
  • Liujun He,
  • Qinhao Liang,
  • Siyao Tang,
  • Jie Xie,
  • Ting Long,
  • Jing Hou,
  • Wootae Kim,
  • Fei Zhao

摘要

Breast cancer remains the leading cause of cancer-related mortality among women worldwide. Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a critical therapeutic option, particularly for patients with triple-negative breast cancer and other HER2-negative metastatic breast cancer harboring BRCA mutations. Despite their clinical success, the emergence of primary and acquired resistance to PARP inhibitors poses a significant challenge, limiting their long-term effectiveness. Here we provide a comprehensive overview of the mechanisms underlying the action of PARP inhibitors, as well as their clinical development and application. In addition, we discuss the factors driving resistance and potential strategies to overcome it in the context of PARP inhibitors.